Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

REPLIMUNE GROUP, INC. Financing Cash Flow

REPLIMUNE GROUP, INC. (REPL) reported Financing Cash Flow of $800.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14

  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $800.00K.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $55.68M.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $10.45M, a 93.30% decline year-over-year.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $324.00K.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for fiscal 2026 was $66.29M, a 73.73% decline from fiscal 2025.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for fiscal 2025 was $252.40M, a 1450.06% increase from fiscal 2024.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for fiscal 2024 was $16.28M, a 94.77% decline from fiscal 2023.
  • REPLIMUNE GROUP, INC. net cash provided by (used in) financing activities for fiscal 2023 was $311.30M, a 4618.14% increase from fiscal 2022.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30$800.00K
10-Q · filed 2026-08-14
$56.48M
derived: sum of 2 quarters · filed 2026-08-14
$66.93M
derived: sum of 3 quarters · filed 2026-08-14
$67.25M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$55.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$66.13M
derived: sum of 2 quarters · filed 2026-06-29
$66.45M
derived: sum of 3 quarters · filed 2026-06-29
$66.29M
10-K · filed 2026-06-29
2025-12-31$10.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03
$10.78M
derived: sum of 2 quarters · filed 2026-02-03
$10.62M
10-Q · filed 2026-02-03
$10.48M
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30$324.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06
$166.00K
10-Q · filed 2025-11-06
$34.00K
derived: sum of 3 quarters · filed 2026-08-14
$155.96M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$158.00K
10-Q · filed 2026-08-14
-$290.00K
derived: sum of 2 quarters · filed 2026-08-14
$155.64M
derived: sum of 3 quarters · filed 2026-08-14
$155.60M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$132.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$155.80M
derived: sum of 2 quarters · filed 2026-06-29
$155.76M
derived: sum of 3 quarters · filed 2026-06-29
$252.40M
10-K · filed 2026-06-29
2024-12-31$155.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-03
$155.89M
derived: sum of 2 quarters · filed 2026-02-03
$252.53M
10-Q · filed 2026-02-03
$252.40M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30-$39.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-06
$96.60M
10-Q · filed 2025-11-06
$96.47M
derived: sum of 3 quarters · filed 2025-11-06
$111.34M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$96.64M
10-Q · filed 2025-08-07
$96.51M
derived: sum of 2 quarters · filed 2025-08-07
$111.38M
derived: sum of 3 quarters · filed 2025-08-07
$111.81M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31-$130.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22
$14.74M
derived: sum of 2 quarters · filed 2025-05-22
$15.18M
derived: sum of 3 quarters · filed 2025-05-22
$16.28M
10-K · filed 2025-05-22
2023-12-31$14.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-12
$15.31M
derived: sum of 2 quarters · filed 2025-02-12
$16.41M
10-Q · filed 2025-02-12
$16.34M
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30$438.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12
$1.54M
10-Q · filed 2024-11-12
$1.47M
derived: sum of 3 quarters · filed 2024-11-12
$272.90M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$1.10M
10-Q · filed 2024-08-08
$1.03M
derived: sum of 2 quarters · filed 2024-08-08
$272.46M
derived: sum of 3 quarters · filed 2024-08-08
$279.89M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$77.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16
$271.36M
derived: sum of 2 quarters · filed 2024-05-16
$278.78M
derived: sum of 3 quarters · filed 2024-05-16
$311.30M
10-K · filed 2024-05-16
2022-12-31$271.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-08
$278.86M
derived: sum of 2 quarters · filed 2024-02-08
$311.38M
10-Q · filed 2024-02-08
$311.74M
derived: sum of 4 quarters · filed 2024-02-08
2022-09-30$7.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-07
$39.95M
10-Q · filed 2023-11-07
$40.30M
derived: sum of 3 quarters · filed 2023-11-07
$44.27M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$32.52M
10-Q · filed 2023-08-03
$32.88M
derived: sum of 2 quarters · filed 2023-08-03
$36.85M
derived: sum of 3 quarters · filed 2023-08-03
$38.00M
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$359.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18
$4.33M
derived: sum of 2 quarters · filed 2023-05-18
$5.48M
derived: sum of 3 quarters · filed 2023-05-18
$6.60M
10-K · filed 2023-05-18
2021-12-31$3.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-09
$5.12M
derived: sum of 2 quarters · filed 2023-02-09
$6.24M
10-Q · filed 2023-02-09
$7.02M
derived: sum of 4 quarters · filed 2023-02-09
2021-09-30$1.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-03
$2.27M
10-Q · filed 2022-11-03
$3.06M
derived: sum of 3 quarters · filed 2022-11-03
$265.25M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$1.12M
10-Q · filed 2022-08-04
$1.91M
derived: sum of 2 quarters · filed 2022-08-04
$264.10M
derived: sum of 3 quarters · filed 2022-08-04
$264.07M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$785.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19
$262.98M
derived: sum of 2 quarters · filed 2022-05-19
$262.95M
derived: sum of 3 quarters · filed 2022-05-19
$372.46M
10-K · filed 2022-05-19
2020-12-31$262.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-03
$262.16M
derived: sum of 2 quarters · filed 2022-02-03
$371.68M
10-Q · filed 2022-02-03
$371.71M
derived: sum of 4 quarters · filed 2022-02-03
2020-09-30-$35.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-04
$109.48M
10-Q · filed 2021-11-04
$109.51M
derived: sum of 3 quarters · filed 2021-11-04
$199.88M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$109.51M
10-Q · filed 2021-08-06
$109.55M
derived: sum of 2 quarters · filed 2021-08-06
$199.91M
derived: sum of 3 quarters · filed 2021-08-06
$209.66M
derived: sum of 4 quarters · filed 2021-08-06
2020-03-31$34.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20
$90.40M
derived: sum of 2 quarters · filed 2021-05-20
$100.15M
derived: sum of 3 quarters · filed 2021-05-20
$100.17M
10-K · filed 2021-05-20
2019-12-31$90.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-04
$100.11M
derived: sum of 2 quarters · filed 2021-02-04
$100.13M
10-Q · filed 2021-02-04
$100.17M
derived: sum of 4 quarters · filed 2021-02-04
2019-09-30$9.75M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-05
$9.77M
10-Q · filed 2020-11-05
$9.81M
derived: sum of 3 quarters · filed 2020-11-05
$9.96M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$18.00K
10-Q · filed 2020-08-07
$59.00K
derived: sum of 2 quarters · filed 2020-08-07
$212.00K
derived: sum of 3 quarters · filed 2020-08-07
$101.60M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$41.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
$194.00K
derived: sum of 2 quarters · filed 2020-06-03
$101.58M
derived: sum of 3 quarters · filed 2020-06-03
$101.39M
10-K · filed 2020-06-03
2018-12-31$153.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-13
$101.54M
derived: sum of 2 quarters · filed 2020-02-13
$101.35M
10-Q · filed 2020-02-13
$101.35M
derived: sum of 4 quarters · filed 2020-06-03
2018-09-30$101.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-12
$101.20M
10-Q · filed 2019-11-12
$101.20M
derived: sum of 3 quarters · filed 2020-06-03
$101.20M
derived: sum of 4 quarters · filed 2020-06-03
2018-06-30-$195.00K
10-Q · filed 2019-08-14
-$195.00K
derived: sum of 2 quarters · filed 2020-06-03
-$195.00K
derived: sum of 3 quarters · filed 2020-06-03
2018-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
$0.00
derived: sum of 2 quarters · filed 2020-06-03
$54.75M
10-K · filed 2020-06-03
2017-12-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-02-14
$54.75M
10-Q · filed 2019-02-14
2017-09-30$54.75M
10-Q · filed 2018-11-14
2017-03-31$15.00M
10-K · filed 2019-06-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B